The presence of TILs and PD1/PDL1 expression in the tumor microenvironment of TNBC has been reported in many studies to correlate with a better outcome and to predict response to immunotherapy with anti-PD1/PDL1 inhibitors50–56. This evidence concerns the gene CD274 and neoplasm.